


# At a Glance

## Daiichi Sankyo Overview

FY2023 results

Number of employees



Number of global employees

**18,726**

Countries/regions with Group presence

**30 countries and regions**


R&D locations

**20 sites**

Production locations

**13 sites**

Revenue by Region



## Strengths in



### Human Resources

- Diverse range of talents with high levels of expertise
- Scientific assessment capabilities
- Technologies originated from craftsmanship
- High levels of engagement
- Desire for innovation

### Core Technologies

- Proprietary ADC technology platform
- Protein engineering, medicinal chemistry
- Pharmacological efficacy, translational research, and research DX infrastructure to support the above

### Corporate Culture

- A corporate culture in which employees respect each other as a specialist in science, and exchange opinions in a free and open-minded manner, regardless of positions and tenure
- A culture that promotes the transmission of experience and technologies for creating medicines
- Intelligent Failure, a culture to learn from mistakes
- Penetration of Core Behaviors with the aim of fostering One DS Culture


## Financial Highlights

FY2023 results

Revenue



Core Operating Profit (Amount and Ratio before R&D Expense)



Major Products Worldwide ( Enhertu® / Lixiana® )



R&D Expenses (Amount and Ratio)



ROE



DOE\*



\*Dividend on Equity = Total dividend amount / Equity attributable to owners of the Company

## Non-Financial Highlights

FY2023 results

CO<sub>2</sub> emissions reduction rate (compared to FY2015 level)



Number of countries and regions where Enhertu has been launched / Number of patients treated



Positive Response Rate in Engagement Survey



Ratio of Female Senior management employees\*



\*Female employees in the position of division head or equivalent or higher